cyrilzakka/clinical-trials huggingface dataset:
Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization

Direct oral anticoagulants (Rivaroxaban, Apixaban and Dabigatran) are an alternative to anti-vitamin K drugs and low molecular weight heparins in many cardiovascular diseases.

This new class of anticoagulants represents a particular and very promising advance: they are administered orally, their mechanism of action is rapid and direct on coagulation and their predictable pharmacological action allows for administration at fixed doses. In contrast to anti-vitamin K, there is no need for routine biological monitoring.

However, their therapeutic range is narrow and there is no routine biological monitoring. Rigorous compliance is therefore necessary. In addition, there are no official validated recommendations either for the measurement of anticoagulant activity in certain emergency situations, or for the management of severe bleeding (except recently for Pradaxa®).

Their correct use requires the training and involvement of health professionals as well as information and support for patients.

Pharmaceutical interviews are one of the main ways in which pharmacists can ensure this security through personalized and optimal patient care.

The purpose of these interviews is to:

* Reinforce the pharmacist's advisory, educational and preventive roles with patients;
* To enhance the pharmacist's expertise in the area of medication;
* To evaluate the patient's knowledge of his or her treatment;
* To assess the patient's knowledge of his or her treatment; To seek the patient's therapeutic adherence and help him or her to take ownership of his or her treatment;
* To evaluate, in the long term, the patient's appropriation of his or her treatment.

In this way, they enable involvement with patients while providing a link between healthcare professionals, which is essential for optimal patient care.

In recent years, numerous studies have been conducted on pharmaceutical interviews in the United Kingdom and the Netherlands.

On the other hand, few studies have been conducted in France to evaluate the clinical impact of pharmaceutical interviewing in medical services.

The aim of this study is to compare patients' knowledge of direct oral anticoagulants between 2 cardiology departments offering or not a pharmaceutical interview.


Eligibility Criteria:
Inclusion Criteria:

* Patient hospitalized for more than 48 hours in a cardiology department with a discharge prescription for curative anticoagulation.
* Indication for a direct oral anticoagulant for atrial fibrillation, deep vein thrombosis or pulmonary embolism

Exclusion Criteria:

* Patients treated for the prevention of venous thromboembolic disease who have undergone scheduled total hip replacement or total knee replacement surgery.
* Patient with cognitive impairment
* Patients with a previous prescription for a direct oral anticoagulant
Retracting the Esophagus During AF Ablation

This Study is designed to determine the outcome and effect of implementation of Esophageal Stylet as a strategy to minimize the risk of esophageal injury during the atrial fibrillation catheter ablation procedure.

There is a clear potential to produce transmural esophageal injury during catheter ablation for AF when employing a lesion set targeting the posterior left atrial wall and pulmonary vein (PV) antra using contemporary large-tip or irrigated-tip catheter ablation systems when endocardial target sites are in close proximity to the esophagus.

It is very likely that a movement by the Esophageal Stylet of only 2 to 3 centimeters from the midline can safely protect the esophagus from thermal injury and will mimic the natural migration of the esophagus itself.

The Stylet proposes to safely facilitate lateral esophageal movement in a manner consistent with the esophagus's own natural migration in order to displace and maintain the esophagus's position away from potential damage resulting from a cardiac ablation procedure in the left atrium or coronary sinus.

The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters. Other common procedures, such as (Trans-esophageal Echocardiogram), move the esophagus twice this distance with a low risk.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 or above for the Patient or legal representative to provide informed consent.
2. Documented paroxysmal or persistent Atrial Fibrillation by a Cardiologist and EKG finding.
3. The patient will undergo Atrial Fibrillation catheter ablation as a treatment plan.

Exclusion Criteria:

1. Bleeding disorder.
2. Dysphagia to solid and liquid or any documented esophageal masses or cancer.
3. Esophageal varices, diverticulum, esophageal web, upper GI bleeding, or hiatal hernia.
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo

Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release of the neurotransmitter dopamine in the brain. The purpose of this study is to further examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence.

This randomized, double-blind dose study will compare the effectiveness of three active medication doses of dextro-amphetamine sulfate to placebo in the treatment of cocaine dependence. Participants will be randomly assigned to one of the four following dosages of dextro-amphetamine sulfate: 0 mg, 40 mg, 60 mg, or 80 mg. Participants will undergo a 2-week stabilization period followed by a 25-week study period. The study period will include administration of the stable medication dose for 21 weeks, followed by 1 week of dose reduction, and then 3 weeks without medication. All participants will receive weekly cognitive behavioral therapy and electrocardiograms. Participants will be given the option to participate in a voluntary plasma blood draw during Weeks 4, 8, and 20 and will be scheduled for follow-up assessments at Months 1 and 3 post-treatment.

Eligibility Criteria:
Inclusion Criteria:

* DSM-IV diagnosis of cocaine dependence, as determined by the Structured Clinical Interview for DSM-IV
* Agreement to use an adequate method of contraception for the duration of the study
* Electrocardiogram confirmation by a cardiologist
* Cocaine-positive urine test prior to study entry

Exclusion Criteria:

* High blood pressure
* Significant heart disease
* Clinically significant cardiovascular abnormality
* Angina
* Kidney, liver, or gastrointestinal disorder
* Current Axis I disorder not related to drug use
* Current dependence on any drug other than nicotine
* Attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
* On probation or parole for reasons other than those related to drug abuse charges
* Pregnant or breastfeeding
* Sought treatment for drug dependence within 3 months prior to study entry
* Currently taking prescribed medications
Prevalence Study of Amyloidosis in Patients With Surgery of Suspect Bilateral Carpal Tunnel (AMYLYONCARP)

The purpose of this study is to evaluate the prevalence of amyloidosis in population of patient affected by suspect bilateral carpal tunnel with indication of surgery


Eligibility Criteria:
Inclusion Criteria:

* bilateral carpal tunnel with indication of surgery and judged suspect:
* age of 50 years old and more
* non-traumatic or undetermined neuropathic etiology or cardiac history (atrial arrhythmia or Heart Failure or cardiac stimulation) or family history of hereditary amyloidosis or monoclonal gammopathy

Exclusion Criteria:

* patient with diagnosis of amyloidosis
* traumatic bilateral carpal tunnel or linked to rheumatoid arthritis
Impact of Perioperative Body Composition Abnormalities on Patient Outcomes After Liver Transplantation

Accumulating evidence suggests the prognostic significance of body composition in chronic diseases and neoplastic diseases. CT imaging-based body composition abnormalities are significantly associated with post-LT adverse outcomes including decreased quality of life (QOL), impaired graft regeneration and mortality. However, the perioperative changes in body composition and their potential clinical implications remain unexplored. The objective of this study is to systematically explore and clarify the correlation between body composition and the prognosis of liver transplant patients through dynamic peri-transplant mornitoring.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients undergoing deceased donor liver transplantation (DDLT) for the first time.

Exclusion Criteria:

* Pediatric transplants
* Re-transplants
* Multi-organ transplants
* Liver cancer patients with macrovascular invasion or distant metastasis
* Patients who died within 30 days after transplantation
Promotion of Self-help Strategies for Depression

The purpose of this study is to investigate the effectiveness of health promotion emails for depression. It is hypothesised that emails containing self-help advice will improve depression symptoms more than emails containing information about depression.

Depression symptoms are commonly experienced and disrupt day-to-day life. Increasing depression literacy and the use of effective self-help methods could improve depression across the community. The internet is an ideal promotional medium for health messages, because it is often used to search for information about mental health issues, and health messages can be widely disseminated at little cost. An email campaign could be a low-cost approach to improving self-help behavior and knowledge about depression in adults with depression symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Access to the internet at least once per week
* Resident of Australia, New Zealand, Canada, Ireland, United Kingdom, USA

Exclusion Criteria:
Feasibility of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)

Delirium is common in older emergency department (ED) patients and often remains unrecognized. Existing instruments to detect delirium are often time consuming and therefore not feasible in the busy ED setting In this study the investigators tested the feasibility of the newly developed modified confusion assessment method (mCAM-ED).


Eligibility Criteria:
Inclusion Criteria:

* patients aged 65 or older

Exclusion Criteria:

* patients treated in the resuscitation room
* patients transferred or discharged within 2 hours of arrival
* patients with insufficient proficiency in the German language
* patients with an inability to communicate (e.g. aphasic patients)
The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects

A Phase 1, First-in-human, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 after Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects

DWP213388 will be administered to the study subjects, according to a randomized, double-blind, and placebo-controlled design. The administration will be a single or multiple oral doses for healthy subjects.

Eligibility Criteria:
Inclusion Criteria:

1. Willing to sign an Institutional Review Board (IRB) approved informed consent form (ICF) on a voluntary basis and to voluntarily participate in the study, after being fully informed of and completely understanding this study, prior to any screening procedure being undertaken.
2. Healthy adult male or female subject, of any race, between 18 to 65 years of age, inclusive at time of signing the ICF and prior to study intervention administration.
3. Body mass index (BMI) between 18.0 and 34.9 kg/m2 at Screening.
4. Subject who is determined to be in good health based on the results of medical history, physical examinations, 12-lead ECG, vital signs, and clinical laboratory evaluations at Screening or Day -1 as assessed by the Investigator (or designee).

Exclusion Criteria:

1. Subject has significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).

   attacks
2. Subject has fasting blood glucose \> 110 mg/dL (\> 6.1 mmol/L) (confirmed with repeat testing if required) at Screening.
3. Subject has a history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). Please note subjects with allergies which can be managed without treatment can be included based on the decision of the Investigator (or designee).
4. Subject has a history of stomach or intestinal surgery or resection, including cholecystectomy, that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.

* Patients will be randomly assigned to initial treatment with either rosiglitazone or placebo orally twice daily, every day as long as there is no disease progression or serious side effects. Patients will be asked to complete a drug log to keep track of the medication.
* Before treatment begins the following tests will be performed: physical exam; bone scan; blood work (including PSA level test) and a urine sample.
* While on this study the following tests and procedures will be done once a month: review of side effects and routine blood tests (including PSA levels).
* While on this study the following tests and procedures will be done on months 2 and 4: review of side effects; routine blood tests (including PSA levels) and urine tests.
* If the patient's disease progressed the treatment code will be broken and if the patient was on placebo, they will have the option to begin taking rosiglitazone.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate
* Biochemical disease progression following local therapy defined as three rises in PSA with each PSA determination at least 4 weeks apart and each PSA value \> or = 0.2ng/ml
* For men treated with radical prostatectomy, PSA \> or = 2 ng/ml
* For men treated with primary radiation therapy or post-prostatectomy radiation therapy, PSA \> or = 2 ng/ml and \> 150% post-radiation nadir
* Not an appropriate candidate for salvage radiation therapy or salvage prostatectomy
* Baseline PSADT \< 24 months
* CALGB performance status of 0,1 or 2

Exclusion Criteria:

* Metastatic disease
* Prior hormonal therapy for recurrent prostate cancer
* Prior chemotherapy for prostate cancer
* Current treatment with insulin or an oral hypoglycemic
* History of treatment with thiazolidinediones
* Radiation therapy within 6 months
* SGOT \> 1.5 x ULN
* Fasting blood glucose \< 60 mg/dl
* NYHA Class 3 or 4 cardiac status
The Effect Of Traınıng On Breastfeedıng Gıven To Fathers On Breastfeedıng, Parent-Baby Bondıng And Breastfeedıng Self-Effıcacy Level

The most suitable food for babies is breast milk. It is known that breastfeeding, beyond providing nutrition, has many health benefits for the baby and the mother. The World Health Organization (WHO) recommends that babies start breastfeeding within 1 hour after birth and breastfeed exclusively without any additional food, including water, for the first 6 months. After six months, complementary foods should be started, and the baby should continue to be breastfed for two years or more. On the other hand, between 2015-2020, the rates of infants aged 0-6 months fed with breast milk alone are approximately 44% worldwide.

There are many factors that affect the time of initiation of breastfeeding and the duration of breastfeeding. Some of those; maternal education, mode of delivery, birth weight and socio-economic status. Another influential factor is paternal support. Fathers may want to be involved in breastfeeding education and support their spouses in this process. However, the reasons such as not taking part in the trainings and not being asked direct questions about breastfeeding may cause fathers to feel excluded in this process. It is important to include fathers in education and interventions to achieve breastfeeding goals. Mothers who are supported by their spouses during the breastfeeding process experience breastfeeding problems less and can cope with these problems better.

Today, it is known that fathers are not given sufficient importance in promoting breastfeeding. Including fathers in breastfeeding education can increase the rate and duration of breastfeeding of infants. This study was planned to determine the effect of breastfeeding education given to mothers and/or fathers in the postnatal period on breastfeeding, parent-infant attachment and breastfeeding self-efficacy. The aim of the study is to draw attention to the importance of father support in breastfeeding.


Eligibility Criteria:
Inclusion Criteria:

* Parent's consent to participate in the research
* Parents must be at least primary school graduates
* Mothers and fathers to participate in the study must be 20 years or older
* The mother's first pregnancy (primiparous pregnant)
* Having a smart mobile phone of the mother and father
* The baby is born at term

Exclusion Criteria:

* Experiencing communication problems with parents (mother and father cannot speak and/or understand Turkish, etc.)
* Having or developing a health problem in the mother or baby
* Separation of the mother from her baby for any reason after birth
Cognitive Behavioral Therapy (CBT) for Nightmares in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans

The purpose of this study is to compare the effectiveness of two talk therapies for OEF/OIF Veterans at the Michael J. Crescenz and the West Haven VA Medical Centers. Participants will randomly receive one of two individual treatments intended to improve the sleep disturbance and nightmares of returning Veterans.

This is a dismantling study with the objective of determining whether imagery rehearsal is essential to the efficacy of imagery rehearsal + CBT-I for improving the sleep and nightmare disturbance in Veterans with PTSD and recurrent nightmares.

Eligibility Criteria:
Inclusion Criteria:

* Currently enrolled in treatment in the Michael J. Crescenz VA Medical Center or VA Connecticut Healthcare System Mental Health Clinic
* Meets DSM-IV-R criteria for current PTSD (within the past month)
* Repetitive, military-related nightmares (at least 1 every 2 weeks, for at least 6 months)
* A global sleep disturbance, as indicated by a score of five or greater on the Pittsburgh Sleep Quality Index
* Ability to read and speak English
* A concurrent anxiety disorder or depressive disorder diagnosis will be allowed
* Dementia related to head injury and amnestic disorder related to head injury will be allowed

Exclusion Criteria:

* Current substance dependence
* Bipolar disorder
* Delirium
* Dementia that is not related to head injury
* Amnestic disorder that is not related to head injury
* Schizophrenia and other psychotic disorders
* Severe traumatic brain injury, as indicated by self-report (loss of consciousness or alteration of mental status greater than 24 hours, or peri-traumatic memory loss, or any posttraumatic amnesia greater than 7 days)
* The presence of diagnosed sleep disorders other than insomnia: narcolepsy, circadian rhythm sleep disorders, and periodic limb movement disorder. Participants in treatment for sleep apnea, or who have not benefited from or declined available treatment may be included.
Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)

Pilot study to compare the efficacy and safety of a premixed-insulin regimen (70% intermediate insulin and 30% regular insulin) to a basal-bolus insulin regimen (glargine once daily and glulisine before meals) hospitalized patients with type 2 diabetes.

Pilot, randomized, prospective, open-label study admitted to the Hospital with a previous diagnosis of type 2 diabetes or with a blood glucose level on admission greater than 180 mg/dl.

Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus regimen with glargine once daily and glulisine before meals (Lantus® and Apidra®, Sanofi-Aventis).

The primary outcome of the study was to determine differences in glycemic control between treatment groups as measured by mean daily blood glucose concentration during the hospital stay. Secondary objectives were to determine differences in the percentage of glucose measures between 80 and 180 mg/dl, frequency and severity of hypoglycemic events, total daily insulin use, length of hospital stay and glycemic viability between groups.

Eligibility Criteria:
Inclusion Criteria:

* Previous diagnosis of type 2 diabetes with a blood glucose level on admission greater than 180 mg/dl and treated with diet, any combination of oral antidiabetics agents and/or insulin therapy

Exclusion Criteria:

* Patients with hyperglycemia without a previous diagnosis of diabetes
* Patients with acute hyperglycemic emergencies or with severe hyperglycemia treated with intravenous insulin infusion on admission
* Patients with acute or chronic kidney disease (serum creatinine greater than 2 mg/dl),
* Patients treated with corticosteroids
* Patients with history of severe or repeated hypoglycemic episodes
* Pregnant women
* Patients expected to require ICU admission or less than 3 days of hospital stay
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients

The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients

The risk of developing an eating disorder is increased in type 1 diabetes patients and associated with a poor prognosis in terms of glycemic control, metabolic complications, degenerative complications, and mortality.

Therefore the terminology diaboulimia has emerged to characterize an eating disorder specific to type 1 insulin-dependent diabetes patients, with insulin under dosage with a view of losing or controlling weight and that can contribute to a deterioration of the body composition.

The purpose of this study is to determine the prevalence of eating disorders in an adult cohort with type 1 insulin-dependent diabetes.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient over 18 years of age with type 1 diabetes treated with a subcutaneous insulin pump
* Patient followed up for a subcutaneous insulin pump treatment by the healthcare provider, participating in the study (Agir à Dom group).
* Beneficiary of social security coverage.

Exclusion Criteria:

* Patient with type 2 diabetes or MODY diabetes
* Patient wearing a pacemaker
* Breastfeeding or pregnant woman
* Deprived of liberty by judicial or administrative decision
* Legal guardianship